UstekinumabEtanerceptIxekizumabBrodalumabTildrakizumabGuselkumab=21,5 (N=23); IxekizumabRisankizumabAdalimumabGuselkumabSecukinumab
…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…